Cellectar Biosciences Inc Quick Ratio (CLRB) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cellectar Biosciences Inc   (NASDAQ: CLRB)

Cellectar Biosciences Inc 's Quick Ratio

CLRB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 1.71 below Cellectar Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 303 other companies have achieved higher Quick Ratio than Cellectar Biosciences Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 977 to 1367.

Explain Quick Ratio?
How much Cash & cash equivalents CLRB´s has?
What are CLRB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLRB Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change -17.84 % -50.02 % -76.2 % -61.73 % -79.17 %
Y / Y Cash & cash equivalent Change -39.97 % -43.34 % -63.36 % -57.32 % -65.26 %
Quick Ratio MRQ 1.71 2.84 2.61 1.91 2.34
CLRB's Total Ranking # 1367 # 977 # 889 # 947 # 781
Seq. Current Liabilities Change 4.82 % -3.46 % -16.6 % -2.66 % -36.23 %
Seq. Cash & cash equivalent Change -36.75 % 5.11 % 13.71 % -20.6 % -40.29 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 304
Healthcare Sector # 530
Overall Market # 1367


Quick Ratio Statistics
High Average Low
16.6 4.1 0.38
(Dec 31 2020)   (Dec 31 2023)




Financial Statements
Cellectar Biosciences Inc 's Current Liabilities $ 5 Millions Visit CLRB's Balance sheet
Cellectar Biosciences Inc 's Cash & cash equivalent $ 8 Millions Visit CLRB's Balance sheet
Source of CLRB's Sales Visit CLRB's Sales by Geography


Cumulative Cellectar Biosciences Inc 's Quick Ratio

CLRB's Quick Ratio for the trailling 12 Months

CLRB Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -60.22 % -71.04 % -71.01 % -58.19 % -43.79 %
Y / Y Cash & cash equivalent TTM Growth -53.62 % -58.93 % -44.6 % -12.66 % 31.99 %
Quick Ratio TTM 2.24 2.39 2.35 2 1.92
Total Ranking TTM # 3864 # 2959 # 3130 # 2657 # 2525
Seq. Current Liabilities TTM Growth -5 % -18.02 % -37.38 % -18.43 % -30.84 %
Seq. Cash & cash equivalent TTM Growth -10.96 % -16.6 % -26.31 % -15.24 % -21.16 %

Quick ratio ranking by company, industry and sector >> Back to CLRB Financial Strength Comparisons >> Go to Compare CLRB Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CLRB's Current Liabilities to $4.87 millions, cumulative Quick Ratio to 2.24 below the CLRB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Cellectar Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2959 to 3864.

Explain Quick Ratio?
How much Cash & cash equivalents CLRB´s has?
What are CLRB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 880
Within the Market # 3864


trailing twelve months Quick Ratio Statistics
High Average Low
12.96 4.3 0.66
(Sep 30 2021)   (Mar 31 2016)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Kalvista Pharmaceuticals Inc   4.69 $ 285.030  Millions$ 60.817  Millions
Oragenics Inc   4.67 $ 6.107  Millions$ 1.308  Millions
Abeona Therapeutics Inc   4.64 $ 168.271  Millions$ 36.290  Millions
Cytokinetics Incorporated  4.59 $ 818.550  Millions$ 178.225  Millions
Edesa Biotech Inc   4.57 $ 10.000  Millions$ 2.188  Millions
Septerna Inc   4.44 $ 347.401  Millions$ 78.165  Millions
Gain Therapeutics inc  4.39 $ 16.539  Millions$ 3.770  Millions
Atossa Therapeutics Inc   4.27 $ 31.828  Millions$ 7.457  Millions
Zevra Therapeutics Inc   4.27 $ 200.616  Millions$ 47.028  Millions
Larimar Therapeutics Inc   4.20 $ 200.385  Millions$ 47.757  Millions
Bio Green Med Solution Inc   4.19 $ 3.339  Millions$ 0.796  Millions
Syndax Pharmaceuticals Inc   4.19 $ 361.239  Millions$ 86.174  Millions
Reshape Lifesciences Inc  4.10 $ 8.796  Millions$ 2.144  Millions
Marker Therapeutics inc   4.10 $ 14.916  Millions$ 3.638  Millions
Ars Pharmaceuticals Inc   4.05 $ 200.969  Millions$ 49.612  Millions
Palatin Technologies Inc   4.01 $ 10.159  Millions$ 2.536  Millions
Entrada Therapeutics Inc   3.98 $ 76.444  Millions$ 19.195  Millions
Lisata Therapeutics Inc   3.94 $ 13.060  Millions$ 3.315  Millions
Arcus Biosciences Inc   3.93 $ 822.000  Millions$ 209.000  Millions
Maravai Lifesciences Holdings Inc   3.89 $ 165.922  Millions$ 42.622  Millions
Serina Therapeutics Inc   3.87 $ 24.526  Millions$ 6.340  Millions
Aclaris Therapeutics Inc   3.85 $ 105.416  Millions$ 27.370  Millions
Genelux Corporation  3.77 $ 26.209  Millions$ 6.956  Millions
Scynexis Inc   3.73 $ 59.263  Millions$ 15.900  Millions
Gt Biopharma Inc   3.69 $ 8.923  Millions$ 2.416  Millions
Pulmatrix Inc   3.67 $ 3.324  Millions$ 0.905  Millions
Acurx Pharmaceuticals inc   3.66 $ 9.255  Millions$ 2.527  Millions
Longeveron Inc   3.63 $ 15.758  Millions$ 4.345  Millions
Reviva Pharmaceuticals Holdings Inc   3.63 $ 22.190  Millions$ 6.119  Millions
Xilio Therapeutics Inc   3.62 $ 150.333  Millions$ 41.576  Millions

Date modified: 2026-09-08T17:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.